CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL-17 expression and multiple myeloma progression
Jingya Wang,Ziyi Peng,Jing Guo,Yixuan Wang,Sheng Wang,Hongmei Jiang,Mengqi Wang,Ying Xie,Xin Li,Meilin Hu,Yangyang Xie,Hao Cheng,Tiantian Li,Linchuang Jia,Jia Song,Yafei Wang,Jian Hou,Zhiqiang Liu
DOI: https://doi.org/10.1158/2326-6066.cir-23-0088
IF: 10.1
2023-08-18
Cancer Immunology Research
Abstract:In multiple myeloma (MM), bone marrow stromal cells (BMSCs) shape a unique niche within the bone marrow, promoting T-cell dysfunction and driving MM progression; however, the precise underlying mechanisms remain elusive. Here, we show that BMSC-mediated reprogramming of MM cells led to heightened production of CXCL10. CXCL10 orchestrated the recruitment of γδ T cells into the bone marrow, and this was observed in both the Vk*MYC and 5TGM1 mouse models of MM, as well as in patients experiencing refractory or relapsed MM. Furthermore, the dysfunctional γδ T cells in the MM bone-marrow niche exhibited increased PD-1 expression and IL-17 production. In the Vk*MYC mouse model, MM-associated bone lesions and mortality were markedly alleviated in Tcrd-/- mice, and MM disease progression could be rescued in these mice upon transplantation of γδ T cells expanded from wild-type mice, but not from Il17-/- mice. Mechanistically, the hypoxic microenvironment prevailing in the MM bone-marrow niche stimulated the expression of steroid receptor coactivator 3 (SRC-3) in γδ T cells, which in turn interacted with the transcriptional factor RORγt, promoting Il17 transcription. Pharmacological inhibition of SRC-3 utilizing SI-2 effectively suppressed Il17A expression in γδ T cells, leading to alleviation of MM progression in the murine models and enhancing the anti-MM efficacy of bortezomib. Our results illuminated the bone marrow microenvironment's involvement in provoking γδ T-cell dysfunction throughout MM progression and suggest SRC-3 inhibition as a promising strategy to enhance the effectiveness of immunotherapies targeting γδ T cells.
oncology,immunology